key: cord-0844565-ktrgzhcv authors: Koczulla, Rembert A; Sczepanski, Bernd; Koteczki, Adam; Kuhnert, Stefan; Hecker, Matthias; Askevold, Ingolf; Schneider, Christian; Michel, Sebastian; Kneidinger, Nikolaus title: SARS‐CoV‐2 infection in two patients following recent lung transplantation date: 2020-05-12 journal: Am J Transplant DOI: 10.1111/ajt.15998 sha: be5ae48508464131be3c1d34882b66bcd16a8b77 doc_id: 844565 cord_uid: ktrgzhcv Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that causes Coronavirus disease 2019 (COVID‐19) has become a world spreading health problem with pandemic character. Lung transplant recipients may be particularly at risk due to the high degree of immunosupression and the lung being the organ primarily affected by COVID‐19. We describe a 16‐year old male and a 64‐year old female recently lung transplanted patients with COVID‐19 during inpatient rehabilitation. Both patients were on triple immunosuppressive therapy and had no signs of allograft dysfunction. Both patients had close contact to a person who developed COVID‐19 and were tested positive for SARS‐CoV‐2. Subsequently, both patients underwent systematic screening and SARS‐CoV‐2 was detected ultimately. While the 16‐year old boy was completely asymptomatic, the 64‐year old woman developed only mild COVID‐19. Immunosuppressive therapy was unchanged and no experimental treatment was initiated. No signs of graft involvement or dysfunction were noticed. In conclusion, our report of patients with asymptomatic SARS‐CoV‐2 infection and mild COVID‐19 respectively, may indicate that lung transplant recipients are not per se at risk for severe COVID‐19. Further observations and controlled trials are urgently needed to study SARS‐CoV‐2 infection in lung transplant recipients. Coronarvirus disease , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has become pandemic. Older people and people with comorbidities are at risk for severe COVID-19. 1 Since patients after solid organ transplantation with multimodal immunosuppression are prone to viral infection, 2 the course of SARS-CoV-2 infection remains unknown. The lung is the main organ affected by COVID-19, leading to mechanical ventilator dependent respiratory insufficiency in some cases. Tissue damage in COVID-19 might be mediated by a direct SARS-CoV-2 induced cytopathogenic effect. Therefore, the transplanted lung is likely at particular risk. Impaired mucociliary clearance and the high-degree of immunosuppression might further contribute to disease severity. On the other hand tissue damage might be the consequence of an immune-mediated inflammatory response to the SARS-CoV-2. In this case, immunosuppression might at least in part counteract the hyperinflammatory response to SARS-CoV-2 infection leading to the worst form of COVID- Course and management of COVID-19 in lung transplant recipients remains unknown. Furthermore, differential response to SARS-CoV-2 infection within lung transplant recipients is likely. Time since transplantation and acquired comorbidities might influence the course of disease. Gathering of clinical information is of urgent need. Therefore, the aim of this report is to contribute to the collection of information on COVID-19 in this vulnerable patient population until large-scale studies are available. A 16-year old patient underwent double lung transplantion due to bronchiolitis obliterans after hemaotopoietic stem cell transplantation 15 years ago. The postoperative course was without any complications. The patient received triple immunossupressive therapy with twice daily (b.i.d) This article is protected by copyright. All rights reserved tacrolimus (trough level 12-15 ng/ml), 1000 mg mycophenolate mofetil (MMF) b.i.d. and 15 mg prednisolon once per day (q.d.). Induction therapy was not performed. Trimethoprim/sulfamethoxazole (TMP/SMX) was applied for pneumocystis prophylaxis. Due to low risk CMV-serostatus no prophylaxis with valganciclovir was applied. The patient was referred to our inpatient rehabilition unit approximately 6 weeks after lung transplantation. His clinical presentation was subjectively well and without signs of infection or allograft dysfunction. On admission, partial pressure of oxygen (PaO 2 ) without supplemented oxygen was 90 mmHg (partial pressure of carbon dioxide (PaCO 2 ) was 33 mmHg. Lung function on admission demonstrated values above 100% of predicted. As forced expiratory volume in 1 second (FEV1) was constantly rising, the best post-operative FEV1 was not yet established. Immunosupressive therapy and drug target levels remained unchanged and no experimental antiviral or antiiflammatory treatment for COVID-19 was started. This article is protected by copyright. All rights reserved Once mild lymphopenia (1462/µl), but no eosinopenia was noticed. CRP decreased to normal levels within a few days without antimicrobial therapy as shown in the Table. Immunosuppressive This article is protected by copyright. All rights reserved We provide evidence for mild to asymptomatic COVID-19 infection in highly susceptible patients Recently, two cases of COVID-19 infection in solid organ transplant patients other than lung were reported. 5 In these patients immunosuppressive agents were discontinued upon diagnosis of COVID-19 and methylprednisolone with prophylactic antibiotics were initiated. Both patients developed lung injury and died despite maximal intensive care treatment with mechanical ventilatory support. 5 In contrast, in our present patients the intensive immunosuppressive therapy after recent lung transplantation was not altered. Age is the main contributor for disease severity and outcome, 1 this could be the reason for the asymptomatic course of Case 1. On the other side, Case 2 was female and women are less affected compared to men. Furthermore, comorbidities were not present, as these had been ruled out prior to transplantation. Together these factors might also explain why our patients experienced an oligosymptomatic course of disease. Both patients were systematically screened after exposure to an infected family member and HCP, Recently, Romanelli et al. addressed the potential beneficial role of immunosuppressive drugs as a valid "therapeutic" choice, by reducing the activity of the T-cell immune system and preventing organ injury. 6 The overactivation of the immune system, especially T-cells, manifested by an increase of Th17 and high cytotoxicity of CD8 T-cells might account for the severe immune injury in COVID-19. 7 The anti-inflammatory effects of immunosuppression could diminish the clinical expression of disease. 6, 8 Calcineurin inhibitors reduce the production of interleukin-2, a regulator of proliferation, survival, and maturation for all T-cells. Furthermore, tacrolimus and MMF inhibit interleukin-17 production with a stronger inhibitory effect on Th17. 6, 9, 10 Both Our data do no support that transplantation and related immunosuppression per se predispose to development of severe COVID-19 upon SARS-CoV-2 infection. Our observations may support the continued use of maintenance immunosuppressants. However, whether immunosuppression might protect against severe cytokine storm induced COVID-19 needs to be carefully assessed in larger cohorts. Written informed consent was obtained from both patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster COVID-19 in posttransplant patients-report of 2 cases Accepted Article This article is protected by copyright. All rights reserved Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesis Pathological findings of COVID-19 associated with acute respiratory distress syndrome COVID-19: Yet another coronavirus challenge in transplantation Impact of mycophenolic acid and tacrolimus on Th17-related immune response Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 Accepted Article